Renerve Says Sales Jump 260% in December 2024 Quarter; Shares Rise 7%

MT Newswires Live

01-29

Renerve (ASX:RNV) said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.

The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.

The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.

A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.

The firm's shares rose past 7% in recent Wednesday trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2507215508"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507215508\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2507215508?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-29 12:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507215508","market":"fut","top_or_hot":-1,"title":"Renerve Says Sales Jump 260% in December 2024 Quarter; Shares Rise 7%","media":"MT Newswires Live","content":"<html><body><p> Renerve (ASX:RNV) said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.</p><p>The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.</p><p>The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.</p><p>A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.</p><p>The firm's shares rose past 7% in recent Wednesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Renerve Says Sales Jump 260% in December 2024 Quarter; Shares Rise 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRenerve Says Sales Jump 260% in December 2024 Quarter; Shares Rise 7%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-01-29 12:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Renerve (ASX:RNV) said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.</p><p>The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.</p><p>The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.</p><p>A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.</p><p>The firm's shares rose past 7% in recent Wednesday trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2507215508","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507215508","pubTimestamp":1738125248,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Renerve  said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.The firm's shares rose past 7% in recent Wednesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Renerve表示2024年12月季度销售额增长260%；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNV.AU":0.9},"content_text":"Renerve (ASX:RNV) said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.The firm's shares rose past 7% in recent Wednesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}